We are live on ! Find out more
FGP

Foyston, Gordon, & Payne Portfolio holdings

AUM $434M
1-Year Est. Return 9.09%
This Fund
S&P 500
This Quarter Est. Return
-1.16%
1 Year Est. Return
+9.09%
3 Year Est. Return
+56.86%
5 Year Est. Return
+84.63%
10 Year Est. Return
+238.52%
AUM
$677M
AUM Growth
-$22.6M
Cap. Flow
-$22.5M
Cap. Flow %
-3.32%
Top 10 Hldgs %
41.03%
Holding
76
New
Increased
27
Reduced
29
Closed
5

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$7.11M
2
TDW icon
Tidewater
TDW
+$4.33M
3
JNJ icon
Johnson & Johnson
JNJ
+$2.8M
4
APA icon
APA Corp
APA
+$2.64M
5
MSFT icon
Microsoft
MSFT
+$2.57M

Sector Composition

Rank Sector Weight
1 Healthcare 28.98%
2 Financials 15.71%
3 Technology 11.48%
4 Consumer Staples 10.33%
5 Materials 8.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$36.3B
$39.7M 5.85%
636,573
+10,571
+2% +$615K
MDT icon
2
Medtronic
MDT
$105B
$37.3M 5.51%
478,391
+93,802
+24% +$7.11M
CAG icon
3
Conagra Brands
CAG
$6.88B
$37M 5.47%
1,303,202
-27,211
-2% -$750K
PNC icon
4
PNC Financial Services
PNC
$99.5B
$28.7M 4.24%
308,294
-15,320
-5% -$1.38M
VZ icon
5
Verizon
VZ
$183B
$24.1M 3.55%
494,942
+251
+0.1% +$12.1K
WBA
6
DELISTED
Walgreens Boots Alliance
WBA
$24M 3.54%
282,939
+7,715
+3% +$614K
MSFT icon
7
Microsoft
MSFT
$2.83T
$22.9M 3.38%
563,470
+59,039
+12% +$2.57M
BAX icon
8
Baxter International
BAX
$11.2B
$22.4M 3.31%
602,749
-18,474
-3% -$700K
MET icon
9
MetLife
MET
$59.5B
$22.1M 3.27%
491,608
-2,088
-0.4% -$93.8K
APA icon
10
APA Corp
APA
$12.9B
$19.7M 2.91%
326,276
+41,893
+15% +$2.64M
PFE icon
11
Pfizer
PFE
$143B
$19.2M 2.83%
580,769
+12,472
+2% +$397K
BG icon
12
Bunge Global
BG
$23.7B
$18.5M 2.73%
224,836
-1,749
-0.8% -$149K
JCI icon
13
Johnson Controls International
JCI
$87.4B
$18M 2.66%
341,608
+42,380
+14% +$2.15M
JNJ icon
14
Johnson & Johnson
JNJ
$624B
$18M 2.66%
179,304
+27,489
+18% +$2.8M
CHKP icon
15
Check Point Software Technologies
CHKP
$13.1B
$16.6M 2.44%
201,902
-19,043
-9% -$1.54M
MOS icon
16
The Mosaic Company
MOS
$7.08B
$16.5M 2.44%
358,439
-24,078
-6% -$1.18M
FCX icon
17
Freeport-McMoran
FCX
$91.3B
$16.2M 2.39%
854,177
+125,486
+17% +$2.48M
AVT icon
18
Avnet
AVT
$7.38B
$16.2M 2.39%
363,479
-13,401
-4% -$592K
STT icon
19
State Street
STT
$50.6B
$15.8M 2.33%
214,211
-1,515
-0.7% -$113K
SEM
20
DELISTED
Select Medical
SEM
$12.4M 1.83%
1,554,979
-6,440
-0.4% -$48.1K
TUP
21
DELISTED
Tupperware Brands Corporation
TUP
$12.4M 1.83%
179,344
-23,443
-12% -$1.58M
ICL icon
22
ICL Group
ICL
$6.84B
$12.4M 1.83%
1,744,557
+40,838
+2% +$293K
RGA icon
23
Reinsurance Group of America
RGA
$15.3B
$12.1M 1.79%
129,928
-6,668
-5% -$589K
PPL
24
PPL Corp
PPL
$27.3B
$12.1M 1.78%
384,744
-13,900
-3% -$446K
TDW icon
25
Tidewater
TDW
$3.85B
$11.4M 1.69%
18,526
+4,867
+36% +$4.33M

Similar funds

Foyston, Gordon, & Payne's Q1 2015 Portfolio in Review

As of Q1 2015, Foyston, Gordon, & Payne held 76 positions worth $677M, down 3.2% from $700M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Foyston, Gordon, & Payne withdrew a net $22.5M in Q1 2015, closing 5 positions and reducing 29 holdings. Its most notable exit was COVIDIEN PLC COM SHS NEW (IRELAND), an estimated $16.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 26% a quarter earlier, followed by Financials and Technology.

Against the trend, Foyston, Gordon, & Payne added an estimated $7.11M to Medtronic.

  • Foyston, Gordon, & Payne added most to Medtronic in Q1 2015, an estimated $7.11M increase.
  • Foyston, Gordon, & Payne's biggest Q1 2015 reduction was Diebold Nixdorf Incorporated, cutting an estimated $6.2M.
  • Foyston, Gordon, & Payne fully exited COVIDIEN PLC COM SHS NEW (IRELAND) in Q1 2015, selling an estimated $16.2M.
  • Foyston, Gordon, & Payne's ten largest holdings make up 41% of its $677M portfolio in Q1 2015.
  • Foyston, Gordon, & Payne opened 0 new positions and closed 5 in Q1 2015.
  • Foyston, Gordon, & Payne's portfolio value fell 3.2% quarter-over-quarter to $677M.

Based on Foyston, Gordon, & Payne's 13F filing for Q1 2015, filed 15 May 2015.